"The path to economic recovery begins with reining in senseless regulations placed on business," Bilbray said. "This additional inspection not only costs companies hundreds of thousands of dollars, but it diverts limited time and resources away from research, development and innovation.
The bill, H.R. 4056, would amend the Food, Drug and Cosmetic Act so that duplicative state-level inspections would be eliminated. But it would allow state agencies to conduct facility inspections when a drug or device is thought to pose a threat to public safety, when the federal government orders a recall of a product or if the FDA requests it.